“Chronix has signed an important exclusive commercial deal for 15 years with a clinical laboratory group, which has an NPV, based on a minimum annual number of tests, worth $92 million”, per November 7, 2018 Hardman and Co. Report.
CHRONIX BIOMEDICAL, INC.
Chronix Biomedical, Inc. is a molecular diagnostics company that has developed blood tests that allow you to see if the cancer treatment is effective or if a transplanted organ is being accepted by the patient’s body and is he in healthy condition.
DOCTORS ABOUT OUR TESTS
“The knowledge that we have gained over the past year now suggests to us that we are able to provide to doctors and their patients the ability to diagnose at the most earliest stage the presence of cancer in their body.”
Howard Urnovitz, CEO of Chronix Biomedical for The Times
“We believe our cancer blood tests will lead to a world where no one dies unnecessarily of cancer.”